about
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjectsPharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma.Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma.A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain.Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application.Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.Physicians' attitudes and knowledge concerning antibiotic prescription and resistance: questionnaire development and reliability.Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.Intranasal drug delivery: how, why and what for?Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies.Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review.A critical review of microextraction by packed sorbent as a sample preparation approach in drug bioanalysis.Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles.Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules.Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.Clinical drug-drug interactions: focus on venlafaxine.Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review.Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives.Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays.Dendritic cell-based immunotherapy: a basic review and recent advances.Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.Early preclinical evaluation of dihydropyrimidin(thi)ones as potential anticonvulsant drug candidates.Drug-metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs.Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials.HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: amiodarone used as a model substance.Gastrodia elata and epilepsy: Rationale and therapeutic potential.Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.Determinants of physician antibiotic prescribing behavior: a 3 year cohort study in Portugal.Intranasal Delivery of Topically-Acting Levofloxacin to Rats: a Proof-of-Concept Pharmacokinetic Study.
P50
Q29391915-339101EC-23AB-42B6-AE12-20561F88C37FQ30667842-1DC204FE-9059-4D0A-A6BE-2B17DEA92A6BQ33289016-5A842A03-066A-4EDB-8C2E-970CE545EAD5Q33635606-A9B9FE24-064D-4249-9989-5D3125EA7B68Q33968508-B171C559-5D71-42EF-A166-7F868187F55CQ34375311-85173104-749B-445B-9C21-1512E2114560Q34452500-BB823524-526D-4C3F-A34D-F230CB014678Q34632153-EE403F9B-709C-4A73-9656-A1B69AF9A91DQ34941977-19C1E653-1744-4B22-94B1-8652C6BE76A1Q35683786-293D7153-F012-4860-A20F-3A53EF070FF1Q35889022-9FD5AEE4-9167-4ADF-ACCD-53F826BEB78EQ36688467-C89F86DD-B799-4B9F-9C41-C0BE0FA5523FQ36947574-4946056A-9516-4899-94C4-2F2233ACDC22Q37672691-73FFF9D1-6E95-485C-9EFB-A4E64219980DQ37962094-3982CBAA-68C0-4DDC-B018-A5CC698BF07BQ37968623-0FB748EB-C507-464C-8ADC-90C26329DDAFQ37982661-9632C785-93D5-4420-80A9-7547626653ECQ38057839-56F907E3-16AC-4DEF-BB82-0BF58A629192Q38087673-CA6BB0E3-1801-4FAD-8B51-09A8AD3E346FQ38112479-1D529527-59EB-43F2-9BA8-936B28C417A2Q38177309-B9D757B5-84A9-485C-A022-0802DCBA93DBQ38194380-D4855155-855F-42C9-A802-9A3C90E9C8CDQ38200422-FCFB2C35-3A1A-4E93-BD50-382F16B6DFBCQ38200847-8A2BF27B-5B50-4CC7-AFED-3EA5CC99215CQ38223167-507F99A7-F3AC-4E36-8B20-CFDC2B2A35CAQ38260525-87B61550-E37E-4F4F-A0BC-9A6529A2D612Q38375693-6E107C80-07BC-44BF-8CF6-45DB303419E6Q38571694-0A730B21-39AA-47E6-8370-D6D6E4730AE4Q38607765-B552768B-6F8C-48CF-8B66-1FDAC7001C6FQ38665350-CC45FB44-528E-49ED-B509-6229CEDADC84Q38669163-F0F400EE-8AE8-4E49-B410-FA84A1CF1AD8Q38743304-C8D4AA4A-23AF-4F63-8121-3A5661718C27Q38798867-1D5773E1-2950-4205-8658-7F63B1DB563CQ38819781-9EF3ADE0-A289-4ABB-B4FF-9F0E112F59C7Q38961609-F02CDC1B-D549-4354-9196-50A2134BE072Q38986511-35B88A0F-E1CE-452A-BA37-86C6320AB161Q39037735-3EB4C761-E8F6-4AFD-AE7A-77BDE4F7F35BQ39829073-BC647AF9-F579-44B0-902F-14C5309AC86CQ39996414-66E39E6D-C9B3-462B-A4E0-9AA5B0CDDCC3Q40117762-91632685-ED27-4E9D-8165-2DF95AA34004
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amílcar Falcão
@ast
Amílcar Falcão
@en
Amílcar Falcão
@es
Amílcar Falcão
@nl
type
label
Amílcar Falcão
@ast
Amílcar Falcão
@en
Amílcar Falcão
@es
Amílcar Falcão
@nl
altLabel
A.C. Falcao
@en
Amílcar Celta Falcão
@en
Falcao A.
@en
Falcão A.
@en
Falcão A.C.
@en
prefLabel
Amílcar Falcão
@ast
Amílcar Falcão
@en
Amílcar Falcão
@es
Amílcar Falcão
@nl
P1053
G-6611-2013
P106
P1153
25639474900
P214
6847151172708139210001
P31
P3829
P496
0000-0002-3854-6549
P734
P7859
viaf-6847151172708139210001